May 7, 2021
2 mins read

‘Pfizer-BioNTech vax very effective against UK, SA variants’

Among people 85 or older, the vaccine was more than 94 percent effective at preventing infection, hospitalization, and death…reports Asian Lite News.

The Pfizer-BioNTech Coronavirus vaccine is highly effective against severe pneumonia and death caused by both UK-, South Africa-variants, results of twin studies have shown.

The studies, based on the real-world use of the vaccine in Qatar and Israel, suggested that the vaccine can prevent the worst outcomes caused by B117, the variant first identified in the UK, and B1351, first identified in South Africa, in young and old.

The first study, published in The Lancet, showed that two doses of the Pfizer-BioNTech Covid vaccine are highly effective against Covid-19 for all people over the age of 16 years, providing 95.3 percent protection against infection and 96.7 percent protection against death seven days after the second dose.

Among people 85 or older, the vaccine was more than 94 percent effective at preventing infection, hospitalization, and death. The team from the Israel Ministry of Health used national pandemic surveillance data between January 24 and April 3. There were 232,268 confirmed Covid-19 infections in the country and the most prevalent strain was B117. It accounted for 94.5 percent of specimens tested.

AstraZeneca vaccine

The second study, appearing in the New England Journal of Medicine, is based on information about more than 200,000 people from Qatar’s national Covid-19 databases between February 1 and March 31, the New York Times reported.

In multiple analyses, the researchers found that the vaccine was 87 to 89.5 per cent effective at preventing infection with B117 among people who were at least two weeks past their second shot. It was 72.1 to 75 per cent effective at preventing infection with B1351 among those who had reached the two-week point, the report said.

The vaccine was highly effective at protecting against the worst outcomes. Overall, it was 97.4 percent effective at preventing severe, critical or fatal disease from any form of the coronavirus, and 100 per cent effective at preventing severe, critical or fatal disease caused by B117 or B1351.

“This is really good news. At this point in time, we can confidently say that we can use this vaccine, even in the presence of circulating variants of concern,” Annelies Wilder-Smith, an infectious disease researcher at the London School of Hygiene and Tropical Medicine, was quoted as saying on Thursday.

Also Read-Serum Institute to start vaccine production in London

Read More-US backs vaccine patent waiver plan proposed by India

Previous Story

Kerala Covid tally touches record high

Next Story

Stalin era begins in Tamil Nadu

Latest from -Top News

‘Kill and Dump’ Haunts Balochistan Again

The latest killings have reignited accusations of extrajudicial executions and the use of counterterrorism laws to cover up custodial deaths in Balochistan….reports Asian Lite News Concerns have deepened across Balochistan following the

‘ASEAN Expands, But Keeps Its Soul’

Malaysian Foreign Minister Mohamad Hasan urged ASEAN to uphold its unity and strategic resolve amid intensifying geopolitical tensions and mounting external pressures…reports Asian Lite News Consensus and inclusivity will remain the cornerstones

Bangladesh bends to beat Trump’s blow

Dhaka seeks compromise as Trump’s 35% tariff looms large over key exports; Washington urges worker protections, factory relocation to US…reports Asian Lite News Bangladesh has opened the second round of critical trade

China seethes as US lands F-35s in PH

As US F-35 jets land in the Philippines for the first time, Manila cements its frontline role in Washington’s power play against rising China….reports Asian Lite News The Philippines is rapidly cementing
Go toTop

Don't Miss

UK MPs seek revised immigration bill

The hard-line, anti-immigration section among Conservatives had referred the matter

Email contradicts PM’s claim over evacuation of animals from Afghanistan

In December, former Foreign Office worker Raphael Marshall told MPs